RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.